User:Mr. Ibrahem/Rezafungin

Rezafungin, sold under the brand name Rezzayo, is an antifungal medication used to treat invasive candidiasis, including candidemia. Specifically it is used in adults with few or no alternative treatment options. It is given by slow injection into a vein.

Common side effects include low potassium, fever, diarrhea, nausea, low magnesium, abdominal pain, and constipation. Other side effects may include infusion reactions, sun sensitivity, and liver problems. Safety in pregnancy is unclear. It is in the echinocandin class of medication.

Rezafungin was approved for medical use in the United States in 2023. It is expected to become available in the United States in the summer of 2023 and to be expensive. It received an orphan medication designation in Europe in 2021.